Singapore Shingles Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Singapore · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$6.2 MnPlaceholder estimate
Estimate 2025$6.7 Mn0.1% of the global market
Projected 2034$12.9 Mn 91.7%Adds $6.1 Mn over 9 forecast years
CAGR 2025–20347.5%Faster than 34% of 180 Pharmaceuticals markets here
1 in SingaporeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Singapore Shingles Vaccines Market Analysis Executive Summary
Shingles vaccines prevent herpes zoster, a painful rash caused when the chickenpox virus wakes up again, mostly in older adults.
Key segments of the shingles Vaccines market include type (Recombinant Vaccines and Live Attenuated Vaccines) and age (50-64 Years, 65 Years and Above and Immunocompromised Adults).
Singapore Shingles Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Singapore Shingles Vaccines Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the shingles Vaccines market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the shingles Vaccines market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the shingles Vaccines market.
Competitive Landscape for Shingles Vaccines Market in Singapore
The shingles Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Shingles Vaccines Market in Singapore
Shingles Vaccines in Singapore: rules, payment and research
Therapeutic products need registration with the Health Sciences Authority (HSA).[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.[2] ClinicalTrials.gov lists 1 study on Shingles Vaccines that is recruiting, active or about to start in Singapore.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for shingles Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 GSK
7.2 Merck & Co.
7.3 SK bioscience
7.4 Pfizer
7.5 Curevo
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The shingles Vaccines market can be segmented based on various criteria, including type, age and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Shingles Vaccines right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Shingles Vaccines in context
Singapore compared
Health spending per person: 3,922 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 15 countries we cover in APAC.[1]
Doctors: 2.83 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 14.2% of people (2025). World: 10.4% of people (2025). 7th highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Shingles Vaccines market in Singapore?
Placeholder estimate: about $6.7 Mn in 2025, rising to about $12.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Shingles Vaccines market in Singapore growing?
Placeholder estimate: about 7.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Shingles Vaccines market report cover?
The report splits the market by type (Recombinant Vaccines, Live Attenuated Vaccines), age (50-64 Years, 65 Years and Above, Immunocompromised Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Shingles Vaccines market?
Key players include GSK PLC, Merck & Co., Inc., SK bioscience, Pfizer Inc. and Curevo.
What is driving the Shingles Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the shingles Vaccines market.
Who regulates Shingles Vaccines in Singapore?
Therapeutic products need registration with the Health Sciences Authority (HSA). Source: Health Sciences Authority. Checked 14 Nov 2026.
How is healthcare paid for in Singapore?
MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts. Source: CPF Board, MediShield Life. Checked 14 Nov 2026.
How many clinical trials on Shingles Vaccines are running in Singapore?
1 study is recruiting, active or about to start in Singapore, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
How much research is published on Shingles Vaccines?
PubMed lists 33 papers on Shingles Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Singapore 
China
India
US
Canada
Japan
Germany
Italy
Brazil
France
UK
Saudi Arabia
Ecuador
Spain
Mexico
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Kenya
Aurobindo Pharma
Amneal Pharmaceuticals, Inc
Hikma Pharmaceuticals PLC